Drug-induced movement disorders

Neurologic Clinics

Volumn 33, Issue 1, 2015, Pages 153-174

  Mehta, Shyamal H ^a   Morgan, John C ^b   Sethi, Kapil D ^b,c  

^a MAYO CLINIC   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Merz Pharmaceuticals LLC   (United States)

Author keywords

Dopamine receptor; Drugs; Movement disorder; Tardive dyskinesia; Tardive Dystonia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

AKATHISIA; ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG INDUCED MOVEMENT DISORDER; DRUG INDUCED PARKINSONISM; DYSTONIA; HUMAN; MOTOR DYSFUNCTION; MYOCLONUS; PARKINSONISM; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; TARDIVE DYSKINESIA; TARDIVE DYSTONIA; TARDIVE MYOCLONUS; TARDIVE TREMOR; TREMOR; DYSKINESIA, DRUG-INDUCED; MOVEMENT DISORDERS;

ANTIPSYCHOTIC AGENTS; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; MOVEMENT DISORDERS;

EID: 84918505631     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.09.011     Document Type: Review

References (114)

1. Delay J, Deniker P. Chlorpromazine and neuroleptic treatments in psychiatry. J Clin Exp Psychopathol 1956;17(1):19-24.
2. Uhrbrand L, Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia 1960;1:408-18.
3. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983; 40(10):1113-7 [Research Support, Non-US Gov't Research Support, US Gov't, Non-P.H.S. Research Support, US Gov't, P.H.S.].
4. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management [review]. Drug Saf 2005;28(3):191-208.
5. Flaherty JA, Lahmeyer HW. Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment [case reports]. Am J Psychiatry 1978; 135(11):1414-5.
6. Burkhard PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 2014;20(Suppl 1):S108-12.
7. Suzuki T, Koizumi J, Moroji T, et al. Clinical characteristics of the Pisa syndrome. Acta Psychiatr Scand 1990;82(6):454-7.
8. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management [review]. CNS Drugs 2002;16(3):165-74.
9. Sachdev P. Tardive and chronically recurrent oculogyric crises. Mov Disord 1993;8(1):93-7 [Case Reports Research Support, Non-US Gov't].
10. Schneider SA, Udani V, Sankhla CS, et al. Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs. Mov Disord 2009;24(8):1226-9.
11. Bhatt M, Sethi KD, Bhatia K. Acute and tardive dystonia. In: Sethi KD, editor. Drug-induced movement disorders. New York: Marcel Dekker; 2004. p. 111-28.
12. van Harten PN, van Trier JC, Horwitz EH, et al. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 1998;59(3):128-30 [Research Support, Non-US Gov't].
13. van Der Kleij FG, de Vries PA, Stassen PM, et al. Acute dystonia due to metoclopramide: increased risk in AIDS [case reports]. Arch Intern Med 2002;162(3): 358-9.
14. Neale R, Gerhardt S, Liebman JM. Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys. Psychopharmacology (Berl) 1984;82(1-2):20-6.
15. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs [review]. Psychol Med 1980;10(1):55-72.
16. Matsumoto RR, Hemstreet MK, Lai NL, et al. Drug specificity of pharmacological dystonia. Pharmacol Biochem Behav 1990;36(1):151-5 [Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
17. Keepers GA, Casey DE. Clinical management of acute neuroleptic-induced extrapyramidal syndromes [review]. Curr Psychiatr Ther 1986;23:139-57.
18. Waugh WH, Metts JC Jr. Severe extrapyramidal motor activity induced by prochlorperazine. Its relief by the intravenous injection of diphenhydramine. N Engl J Med 1960;262:353-4.
19. Piecuch S, Thomas U, Shah BR. Acute dystonic reactions that fail to respond to diphenhydramine: think of PCP [case reports letter]. J EmergMed1999;17(3):527.
20. Haskovec L. Akathisie. Arch Bohemes Med Clin 1902;17:704-8.
21. Healy D, Farquhar G. Immediate effects of droperidol. Hum Psychopharmacol 1998;13(2):113-20 [Clinical and Experimental].
22. Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-50 [Research Support, Non-US Gov't].
23. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994;51(12):963-74 [Research Support, Non-US Gov't].
24. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175: 1054-60.
25. Barnes TR, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985;42(9):874-8 [Research Support, Non-US Gov't].
26. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42(4): 233-46.
27. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49(7):538-44 [Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
28. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992;106(4):433-8 [Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
29. Lima AR, Bacalcthuk J, Barnes TR, et al. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia [meta-analysis review]. Cochrane Database Syst Rev 2004;(4):CD001946.
30. Lima AR, Weiser KV, Bacaltchuk J, et al. Anticholinergics for neurolepticinduced acute akathisia [review]. Cochrane Database Syst Rev 2004;(1): CD003727.
31. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry 2010;196(2):89-91.
32. Stryjer R, Rosenzcwaig S, Bar F, et al. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 2010;33(5):219-22.
33. Sethi KD, Patel B, Meador KJ. Metoclopramide-induced parkinsonism [case reports]. South Med J 1989;82(12):1581-2.
34. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2(8411):1082-3.
35. Marti Masso JF, Poza JJ. Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia 1996;11(1): 10-5 [in Spanish].
36. Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson's disease in a Scottish city. Br Med J (Clin Res Ed) 1986;292(6519):534-6 [Research Support, Non-US Gov't].
37. Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011; 29(1):127-48, viii.
38. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatr 1988;51(6):850-4.
39. Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci 1990;2(1):64-6.
40. Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes [comparative study]. Mov Disord 1997;12(3):302-5.
41. Morley JF, Duda JE. Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease. J Parkinsons Dis 2013;4(2):169-73.
42. Brigo F, Erro R, Marangi A, et al. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations [review]. Parkinsonism Relat Disord 2014;20(8):808-14.
43. Marsden CD, Tarsy D, Baldessarani RJ. Spontaneous and drug-induced movement disorders. In: Benson DF, Blumer D, editors. Psychiatric aspects of neurologic disease. New York: Grune and Stratton; 1975. p. 219-65.
44. Klawans HL Jr, Bergen D, Bruyn GW. Prolonged drug-induced parkinsonism. Confin Neurol 1973;35(6):368-77.
45. Farde L, Wiesel FA, Halldin C, et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45(1):71-6 [Comparative Study Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
46. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251(1):238-46 [In Vitro Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
47. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158(3):360-9 [Research Support, Non-US Gov't Review].
48. Eichelbaum M, Kroemer HK, Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity [review]. Toxicol Lett 1992; 64-65(Spec No):115-22.
49. Negrotti A, Calzetti S, Sasso E. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility. Neurotoxicology 1992;13(1): 261-4.
50. Forno LS. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 1969;17(6):557-75.
51. Goetz CG. Drug-induced parkinsonism and idiopathic Parkinson's disease [letter]. Arch Neurol 1983;40(5):325-6.
52. Rajput AH, Rozdilsky B, Hornykiewicz O, et al. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases [case reports]. Arch Neurol 1982; 39(10):644-6.
53. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatr 2010;81(1):5-12.
54. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 2011; 100:601-16.
55. Fann WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976;133(8):940-3 [Clinical Trial Controlled Clinical Trial Research Support, US Gov't, Non-P.H.S.].
56. Kelly JT, Zimmermann RL, Abuzzahab FS, et al. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. Pharmacology 1974;12(2):65-73 [Clinical Trial Comparative Study Controlled Clinical Trial].
57. Shoulson I. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia. Adv Neurol 1983;37:259-66 [Comparative Study Research Support, US Gov't, P.H.S.].
58. Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs. Am J Psychiatry 1980;137(10):1163-72.
59. Jeste DV, Lacro JP, Palmer B, et al. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999;156(2):309-11 [Clinical Trial Comparative Study Research Support, US Gov't, Non-P.H.S. Research Support, US Gov't, P.H.S.].
60. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 [review]. Arch Gen Psychiatry 1982;39(4):473-81.
61. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151-6.
62. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18(4):701-15 [Meta-Analysis Research Support, US Gov't, Non-P.H.S. Research Support, US Gov't, P.H.S.].
63. Woerner MG, Saltz BL, Kane JM, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry 1993;150(6):966-8 [Research Support, US Gov't, P.H.S.].
64. Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978;135(11):1321-4 [Research Support, US Gov't, P.H.S.].
65. Fountoulakis KN, Samara M, Siapera M, et al. Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol 2011;26(5):237-42.
66. Stahl SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration [case reports]. Am J Psychiatry 1980;137(10): 1267-9.
67. Little JT, Jankovic J. Tardive myoclonus [case reports]. Mov Disord 1987;2(4): 307-11.
68. Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992;7(1):53-7 [Case Reports Research Support, Non-US Gov't].
69. Keegan DL, Rajput AH. Drug induced dystonia tarda: treatment with L-dopa. Dis Nerv Syst 1973;34(3):167-9.
70. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs [case reports]. Neurology 1982;32(12): 1335-46.
71. Sethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord 1990;5(4):319-21.
72. Yassa R, Nair V, Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand 1986;73(6):629-33.
73. van Harten PN, Matroos GE, Hoek HW, et al. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res 1996;19(2-3):195-203 [Research Support, Non-US Gov't].
74. Chen PY, Lin PY, Tien SC, et al. Duloxetine-related tardive dystonia and tardive dyskinesia: a case report. Gen Hosp Psychiatry 2010;32(6):646.e9-11.
75. Dressler D. Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. J Neural Transm 2014;121(4):367-9.
76. Pellecchia MT, Esposito M, Cozzolino A, et al. Drug induced oromandibular dystonia: A case related to prolonged use of cetirizine. Parkinsonism Relat Disord 2014;20(5):566-7.
77. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1(3):193-208 [Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
78. Kiriakakis V, Bhatia KP, Quinn NP, et al. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121(Pt 11):2053-66.
79. Wojcik JD, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia [comparative study]. Am J Psychiatry 1991;148(8):1055-9.
80. Andersson U, Haggstrom JE, Levin ED, et al. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Mov Disord 1989;4(1):37-46.
81. Bressman SB, de Leon D, Raymond D, et al. Secondary dystonia and the DYTI gene. Neurology 1997;48(6):1571-7 [Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
82. Gimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis. Acta Psychiatr Scand 1985;71(5):488-94.
83. Burke RE, Kang UJ, Jankovic J, et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4(2): 157-75 [Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
84. Schilkrut R, Duran E, Haverbeck C, et al. Course of psychopathologic and extrapyramidal motor symptoms during long-term treatment of schizophrenic patients with psycholeptic drugs (author's transl). Arzneimittelforschung 1978; 28(9):1494-5 [in German, Clinical Trial].
85. Lang AE. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia [case reports review]. Mov Disord 1994;9(2):188-92.
86. Sachdev P. Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale and proposal. Psychopharmacology (Berl) 1994;114(1): 181-6 [Research Support, Non-US Gov't Review].
87. Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord 2014;20(Suppl 1):S113-7.
88. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 2012;27(10):1205-15.
89. Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neurolepticinduced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309(5966):347-9.
90. Ferentinos P, Dikeos D. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry 2012;25(5):381-90.
91. Zhang XY, Zhang WF, Zhou DF, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry 2012;72(8):700-6.
92. De LeonML, Jankovic J.Clinical features andmanagement of classic tardive dyskinesia, tardivemyoclonus, tardive tremor and tardive tourettism. In: Sethi KD, editor. Drug-induced movement disorders. New York: Marcel Dekker; 2004. p. 77-109.
93. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48(2):358-62 [Research Support, Non-US Gov't].
94. Fahn S. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. Adv Neurol 1983;37:267-76.
95. Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia [comparative study]. J Neurol Neurosurg Psychiatr 1974;37(8): 941-7.
96. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013;3. Available at: http:// tremorjournal.org/article/view/161.
97. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;81(5):463-9.
98. Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(5):615-21.
99. Spindler MA, Galifianakis NB, Wilkinson JR, et al. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord 2013;19(2):141-7.
100. Tarsy D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997;20(1):90-3 [Clinical Trial Multicenter Study Research Support, Non-US Gov't].
101. Peritogiannis V, Tsouli S. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature. J Psychopharmacol 2010;24(7):1121-5.
102. Littrell KH, Johnson CG, Littrell S, et al. Marked reduction of tardive dyskinesia with olanzapine [case reports letter]. Arch Gen Psychiatry 1998;55(3):279-80.
103. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12(4):483-96 [Research Support, Non-US Gov't Review].
104. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10 [Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
105. Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatr 2013;6(6):439-51.
106. Albayrak Y, Hashimoto K. Beneficial effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases. Psychiatry Investig 2013;10(4):417-20.
107. Gardos G, Cole JO. Overview: public health issues in tardive dyskinesia. Am J Psychiatry 1980;137(7):776-81 [Research Support, US Gov't, P.H.S.].
108. Gordon MF. Toxin and drug-induced myoclonus [review]. Adv Neurol 2002;89: 49-76.
109. Klawans HL, Carvey PM, Tanner CM, et al. Drug-induced myoclonus. In: Fahn S, Marsden CD, Van Woert MH, editors. Myoclonus. New York: Raven Press; 1986. p. 251-64.
110. Lang AE. Miscellaneous drug-induced movement disorders. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. New York: Futura Publishing; 1992. p. 339-81.
111. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002;58(4):527-36 [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-US Gov't Research Support, US Gov't, P.H.S.].
112. Bharucha KJ, Sethi KD. Movement disorders induced by selective serotonin reuptake inhibitors and other antidepressants. In: Sethi KD, editor. Drug-induced movement disorders. New York: Marcel Dekker; 2004. p. 233-57.
113. Kellett MW, Chadwick DW. Antiepileptic drug-induced movement disorders. In: Sethi KD, editor. Drug-induced movement disorders. New York: Marcel Dekker; 2004. p. 309-56.
114. Sanchez-Ramos J. Stimulant-induced movement disorders. In: Sethi KD, editor. Drug-induced movement disorders. New York: Marcel Dekker; 2004. p. 295-308.